デュアルオレキシン受容体拮抗薬市場レポート：2031年までの動向、予測、競合分析

世界のデュアルオレキシン受容体拮抗薬市場の将来性は、病院・診療所市場と小売薬局市場における機会で有望視されています。世界のデュアルオレキシン受容体拮抗薬市場は、2025年から2031年にかけてCAGR 7.8％で成長すると予想されます。この市場の主な促進要因は、不眠症の有病率の上昇、より良い治療に対する需要の増加、睡眠障害に対する意識の高まりです。

• Lucintel社の予測では、タイプ別ではダリドレキサントが予測期間中に最も高い成長を遂げる見込みです。
• 用途別では、病院・診療所が高い成長を遂げると予測されています。
• 地域別では、北米が予測期間中に最も高い成長が見込まれます。

デュアルオレキシン受容体拮抗薬市場の新たな動向

デュアルオレキシン受容体拮抗薬市場は、薬理学の進歩、睡眠障害の罹患率の上昇、消費者の嗜好の変化などに後押しされ、多くの新たな動向を見せています。オレキシン受容体に関する知識が深まるにつれて、様々な患者のニーズに対応するための新たな適応症や剤形が研究されています。こうした動向はDORA市場の将来を導き、成長機会を生み出しています。

• カスタマイズされた睡眠療法：DORAの方向性の傾向として、カスタマイズされた睡眠療法への移行が見られます。研究の進歩に伴い、遺伝的構造、睡眠行動、様々な病状の素因を考慮し、患者の要求に合うよう個別化された医薬品が増えつつあります。この動向は、睡眠障害の根本的な原因に対処する、より効率的で個別化された治療を可能にし、DORAベースの医薬品をより効果的で安全なものにしています。その結果、個別化治療はDORA市場の主要な構成要素となり、患者に特化した解決策を提供することになります。
• 非習慣性治療：非習慣性睡眠薬に対する需要の高まりがDORA市場を牽引しています。鎮静剤やベンゾジアゼピン系睡眠薬とは異なり、DORAには依存や離脱症状のリスクがないです。このため、DORAは、依存症のリスクのない睡眠障害の長期的な治療を望む患者にとって、ますます魅力的なものとなっています。従来の睡眠薬の使用に伴うリスクに対する認識が高まるにつれて、DORAに対する需要は、特に薬物依存に対する懸念が高い国々で高まると思われます。
• 睡眠障害の併用療法：不眠症やナルコレプシーなどの複雑な睡眠障害を治療するために、二重オレキシン受容体拮抗薬と他の薬剤クラスを併用することへの関心が高まっています。DORAを抗うつ薬や抗精神病薬などの他の治療薬と併用することで、治療全体の効果を高め、複数の基礎疾患を一度に治療することが期待されています。この動向は、DORA市場に新たな治療機会をもたらし、より深刻な健康問題を抱える患者に完全な解決策を提供することになると思われます。
• 他の疾患に対するDORA調査：DORAは主に睡眠障害に利用されていますが、他の神経疾患における治療の可能性を探る動向も見られます。不安、うつ病、さらにはアルツハイマー病などの病気の治療にDORAを利用する方法を発見するための治療が進行中です。DORAは覚醒や覚醒に関与するオレキシン受容体を調節することができるため、より広範な治療の有力な候補となります。この動向は、DORAの市場をより大きくし、神経領域における多目的薬として位置づける可能性があります。
• より多くの薬事承認と臨床試験：DORAが睡眠障害の治療においてその有効性を示し続けるにつれ、より多くの臨床試験が実施され、規制当局もより多くのDORA医薬品を承認するようになっています。睡眠の質を向上させ、世界的に急増する睡眠障害に取り組むことへの関心が高まっているため、DORAに基づく治療に投資する製薬会社が増えています。この動向は治療の選択肢を増やし、新製品の登場と臨床データの蓄積に伴う市場のさらなる成長を促進するはずです。

個別化睡眠治療、非中毒性治療、併用治療に関する研究など、デュアルオレキシン受容体拮抗薬市場の新たな動向は、業界情勢を大きく変えつつあります。これらの動向は、睡眠障害のより効率的で安全な個別化治療への継続的な動きを示すものであり、DORA市場を今後数年間の将来的な成長と革新に向けたものです。

デュアルオレキシン受容体拮抗薬市場の最近の動向

デュアルオレキシン受容体拮抗薬市場は、睡眠障害における研究活動の活発化、規制当局からの承認、製剤の進歩に後押しされ、近年大きな進展を遂げています。これらの進歩はすべて、DORAに基づく治療の有効性を高め、睡眠障害やその他の二次的合併症に苦しむ患者に新たな治療の道を提示しています。市場を塗り替えつつある最も重要な新興国開拓のうち5つを以下に紹介します。

• FDAによるスボレキサントの承認：2014年の米国FDAによるスボレキサント（バルサラ）の承認は、DORA市場にとって大きな指標となりました。このカテゴリーの最初の治療薬として、バルサラは現在、不眠症患者が利用できる最大の治療選択肢の一つとなっています。この承認により、DORAの追加開発への道が開かれ、睡眠導入におけるオレキシン受容体拮抗作用の有効性がさらに強調されました。バルサラの成功は、他の有望なDORA医薬品のさらなる調査を促し、不眠症や睡眠障害の治療法を増やすことになりました。
• 開発中のパイプラインDORA薬：多くの製薬会社が、増大する睡眠薬の需要に応えるため、新規のデュアル・オレキシン受容体拮抗薬を開発しています。これらの薬剤は、不眠症、ナルコレプシー、その他の睡眠関連疾患などの治療における安全性と有効性を確認するため、臨床試験が行われています。DORAの有効性を高め、副作用を減らすことを目的とした絶え間ない調査により、これらの新薬は市場に大きなインパクトを与え、患者により多くの治療選択肢を提供することが期待されています。
• 世界的に広がるDORAの利用可能性：DORAを承認する国が増えたことで、DORAの世界市場は拡大しつつあります。スボレキサントはすでにいくつかの国で認可されており、臨床データが蓄積されるにつれて、さらに多くのDORAベースの薬剤が認可される可能性があります。この成長は、安全で効果的な睡眠薬に対する世界の需要の増加に対応する一助となります。DORA治療薬がより入手しやすくなることで、市場競争力が強化され、世界中の消費者の治療が改善されることが期待されます。
• 非習慣形成療法の重視：従来の鎮静剤の危険性に対する懸念が高まり続ける中、非習慣性睡眠補助薬の開発に重点が置かれています。他の睡眠薬のような依存性のリスクがないDORAがその先導役となっています。患者もヘルスケア専門家も、不眠症やその他の睡眠障害に対して、より安全で長期的な治療法を求めるようになっており、DORAをベースとした治療法の需要が高まっています。
• DORAの適応拡大調査：DORAの睡眠障害以外の適応に関する調査が加速しています。不安障害やうつ病などの神経・精神疾患、アルツハイマー病などの神経変性疾患の治療薬としての可能性が検討されています。これらの研究が成功すれば、DORAの治療領域が飛躍的に拡大し、いくつかの疾患の治療に新たなパラダイムが生まれる可能性があります。この応用範囲の拡大は、市場の拡大と技術革新の原動力となると思われます。

二重オレキシン受容体拮抗薬市場における規制当局の承認、新薬開発、世界のアクセス拡大などの大きな進歩は、睡眠障害の治療におけるさらなる成長と革新につながるものです。より多くの薬剤が市場に投入され、より多くの適応症の研究が進めば、DORA市場は劇的な拡大を遂げ、患者と製薬企業の双方に有利なものとなると思われます。

目次

第1章 エグゼクティブサマリー

第2章 世界のデュアルオレキシン受容体拮抗薬市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 世界のデュアルオレキシン受容体拮抗薬市場の動向（2019～2024年）と予測（2025～2031年）
• タイプ別
  • スボレキサント
  • レンボレキサント
  • ダリドレキサント
• 用途別
  • 病院・クリニック
  • 小売薬局
  • その他

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別
• 北米
• 欧州
• アジア太平洋
• その他地域

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • タイプ別
  • 用途別
  • 地域別
• 世界のデュアルオレキシン受容体拮抗薬市場における新たな動向
• 戦略分析
  • 新製品開発
  • 世界のデュアルオレキシン受容体拮抗薬市場の生産能力拡大
  • 世界のデュアルオレキシン受容体拮抗薬市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Merck
• Eisal
• Idorsia
• Takeda

The future of the global dual orexin receptor antagonist market looks promising with opportunities in the hospital & clinic and retail pharmacy markets. The global dual orexin receptor antagonist market is expected to grow with a CAGR of 7.8% from 2025 to 2031. The major drivers for this market are the rising prevalence of insomnia, the increasing demand for better treatments, and the growing awareness of sleep disorders.

• Lucintel forecasts that, within the type category, daridorexant is expected to witness the highest growth over the forecast period.
• Within the application category, hospital & clinic is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market is seeing a number of emerging trends, fueled by advancements in pharmacology, the rising incidence of sleep disorders, and changing consumer preferences. As knowledge about orexin receptors grows, new indications and drug formulations are being investigated to address various patient needs. These trends are guiding the future of the DORA market and creating opportunities for increased growth.

• Customized Sleep Therapies: A trend in DORA's direction is seen to move toward customized sleep therapies. With growing advancements in research, more medicines are being made personalized to fit patients' requirements specifically, considering their genetic structure, sleep behaviors, and predisposition to various medical conditions. This trend is making it possible to have more efficient and personalized treatments that address the underlying causes of sleep disorders, making DORA-based medicines more effective and safer. Consequently, personalized therapies will be a major component of the DORA market, providing patient-specific solutions.
• Non-Habit-Forming Treatments: Rising demand for non-habit-forming sleep medications is creating a drive in the DORA market. Unlike sedatives and benzodiazepines, DORAs have no risk of dependence or withdrawal symptoms associated with them. This has rendered DORAs increasingly appealing to patients who desire long-term remedies for sleep disorders without the risk of addiction. As people become more aware of the risks associated with the use of conventional sleep medicines, demand for DORAs will increase, particularly in countries where there is high concern about dependency on medications.
• Combination Therapies for Sleep Disorders: There is increasing interest in combining dual orexin receptor antagonists with other drug classes to treat complicated sleep disorders, such as insomnia and narcolepsy. By combining DORAs with other therapeutic drugs, such as antidepressants or antipsychotics, scientists are hoping to enhance the overall effectiveness of treatments and treat multiple underlying conditions at once. This trend will lead to new opportunities for therapy in the DORA market and give patients with more severe health problems complete solutions.
• DORA Research for Other Disorders: Even though DORAs are utilized mostly for sleep disorders, a trend is observed towards exploring their therapeutic potential in other neurological diseases. Studies are in progress to discover how to use DORAs in the treatment of diseases such as anxiety, depression, and even Alzheimer's. Since DORAs can modulate orexin receptors, which are involved in wakefulness and arousal, they are a strong contender for a broader therapy. This trend could make the market for DORAs much larger and position them as multi-purpose drugs within the neurological arena.
• More Regulatory Approvals and Clinical Trials: As DORAs continue to show their efficacy in the treatment of sleep disorders, more clinical trials are being undertaken and regulatory agencies are approving more DORA drugs. The growing interest in bettering the quality of sleep and tackling the worldwide surge in sleep disorders is causing more pharmaceutical firms to invest in DORA-based therapy. This trend should result in an increase in treatment options, fueling further market growth as new products emerge and clinical data continue to accrue.

The new trends in the dual orexin receptor antagonist market, including personalized sleep treatments, non-addictive treatments, and studies on combination treatments, are greatly transforming the industry landscape. These trends are indicative of a continued move towards more efficient, safer, and personalized treatments for sleep disorders, setting the DORA market up for future growth and innovation over the next few years.

Recent Developments in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market witnessed significant progress in recent years, fueled by rising research activity in sleep disorders, approvals from the regulatory authorities, and advancements in formulations. All these advances have enhanced the efficacy of DORA-based treatments, presenting patients suffering from sleep disorders and other secondary complications with new avenues for treatment. Five of the most significant developments that are remaking the market are discussed below.

• FDA Approval of Suvorexant: The US FDA approval of Suvorexant (Balsara) in 2014 was a major benchmark for the DORA market. As the inaugural drug of this category, Balsara is now one of the largest treatment options available to patients of insomnia. This endorsement has opened the door to additional development of DORAs and has highlighted further the effectiveness of orexin receptor antagonism in inducing sleep. The success of Balsara has encouraged further research into other promising DORA drugs, increasing the treatments available for insomnia and sleep disorders.
• Pipeline DORA Drugs in Development: A number of pharmaceutical firms are developing novel Dual Orexin Receptor Antagonists to meet the increasing demand for sleep medicines. The drugs are being tested in clinical trials to determine their safety and effectiveness in the treatment of diseases such as insomnia, narcolepsy, and other sleep-related disorders. With constant research aimed at enhancing the efficacy of DORAs and reducing side effects, these new drugs have the promise to make a significant impact on the market and offer more treatment alternatives for patients.
• DORA Availability Widening Globally: With increased countries approving DORA drugs, the global market for these drugs is widening. Suvorexant has already been licensed in some countries, and more DORA-based medications are likely to be licensed as clinical data continue to accumulate. This growth is assisting in meeting increasing global demand for safe and effective sleep medications. Greater availability of DORA medications will be expected to enhance market competitiveness and make for improved treatment for consumers globally.
• Emphasis on Non-Habit-Forming Therapies: As concerns about the dangers of conventional sedatives continue to grow, efforts are focused on creating non-habit-forming sleep aids. DORAs, which pose no risk of dependence like other sleeping medications, lead the charge. Patients and healthcare professionals alike are increasingly looking for safer long-term cures for insomnia and other sleep disorders, and recognizing this, demand for DORA-based therapies is increasing.
• Expanded Indications Research for DORAs: Research on the application of DORAs for indications other than sleep disorders is picking up speed. Investigations are looking into the possibility of these drugs being used to treat neurological and psychiatric diseases like anxiety, depression, and neurodegenerative conditions like Alzheimer's. If successful, these studies can drastically expand the therapeutic horizon for DORAs and result in new paradigms for the treatment of several diseases. This broadened application would fuel market expansion and innovation.

The major advancements in the dual orexin receptor antagonist market, such as regulatory approval, new drug development, and expanded global access, are leading the way towards additional growth and innovation in treating sleep disorders. With more drugs coming to the market and further research into more indications, the DORA market is set for dramatic expansion, to the advantage of both patients and pharmaceutical firms.

Strategic Growth Opportunities in the Dual Orexin Receptor Antagonist Market

The dual orexin receptor antagonist market offers many strategic growth opportunities in key applications, fueled by a growing awareness of sleep disorders and a growing emphasis on neurological health. These opportunities range across a number of therapeutic areas, from sleep disorders to psychiatric and neurological disorders, and are likely to define the future of the market.

• Growth in Emerging Markets: Emerging markets in Asia, Latin America, and Africa provide ample growth opportunities for the DORA market. With growing awareness of sleep disorders and increasing disposable incomes, demand for effective sleep aids is on the rise. Companies can customize their products to suit the particular requirements of these markets, increasing their reach through localized marketing channels and distribution networks.
• Expansion in Sleep Disorder Treatment: With the increasing incidence of sleep disorders such as insomnia, narcolepsy, and sleep apnea across the world, the market for dual orexin receptor antagonists is likely to grow. By targeting the enhancement of availability and affordability of DORA drugs for the treatment of sleep disorders, pharmaceutical companies can capitalize on this expanding market, particularly as more people look for non-habit-forming, effective treatments.
• Targeting Mental Health Disorders: Investigations into the potential application of DORAs in treating mental health disorders, including depression and anxiety, are creating new opportunities for market expansion. With the increasing demand for treatments that target both sleep disorders and psychiatric disorders, DORAs may provide a two-pronged approach to patient treatment. This potential makes DORAs central drugs for the treatment of sleep and mental health disorders.
• Emphasis on Personalized Medicine: Personalized medicine is taking center stage in the healthcare sector, and the DORA market is no different. By creating customized treatments that take into consideration patient-specific factors, including genetic factors and lifestyle, firms are able to maximize the safety and effectiveness of DORA-based medicines. This trend will propel market growth as patients are increasingly looking for customized treatment solutions that meet their specific needs.
• Combination Therapies with Wider Market Opportunities: Combination therapies of DORAs and other drug types, like antidepressants or antipsychotics, have considerable growth opportunities. These therapies have the goal to treat multiple basic conditions, for example, sleep disorders, anxiety, and depression, within one treatment protocol. Through the presentation of comprehensive remedies, combination therapies of DORAs have a wider market scope and can create new therapeutic avenues for complex diseased patients.

Strategic opportunities for growth in the dual orexin receptor antagonist market, fueled by emerging markets, mental health uses, personalized medicine, and combination therapies, will dramatically reshape the market landscape. Companies that target these opportunities will be well-positioned to succeed in this dynamic and fast-growing market.

Dual Orexin Receptor Antagonist Market Driver and Challenges

The dual orexin receptor antagonist market is influenced by several drivers and challenges such as technological innovations, economic considerations, and regulatory aspects. While they drive the market growth, they also pose challenges that have to be tackled by manufacturers. Through knowledge of these major drivers and challenges, companies can set themselves up for success.

The factors responsible for driving the dual orexin receptor antagonist market include:

1. Increasing Incidence of Sleep Disorders: With the global incidence of sleep disorders, including insomnia and narcolepsy, on the rise, there is a growing need for effective treatments such as dual orexin receptor antagonists. DORAs offer a novel and non-habit-forming alternative to conventional sedatives, fueling market growth.

2. Drug Formulation Innovations: Advances in drug technology are making it possible to develop more potent and targeted DORA-based medications. Innovative formulations that enhance the safety and effectiveness of the drugs are drawing in customers and healthcare professionals, driving the market further.

3. Increased Emphasis on Mental Health: The increased emphasis on mental health and its relationship with sleep disorders is fueling demand for DORA therapies. Addressing both sleep and psychological ailments, DORAs are now being recognized as a feasible treatment option, which is broadening their market scope.

4. Increasing Healthcare Spending: Increasing healthcare spending worldwide is driving the growth of the DORA market, as patients are increasingly opting for medical treatment for their sleep disorders. With increasing disposable income, patients are becoming more inclined to spend money on sophisticated treatments that provide long-term results.

5. Enlarging Clinical Research: Continuous clinical research into the therapeutic potential of DORAs for other neurological and psychiatric disorders, as well as sleep disorders, is a major growth driver for the market. With new indications for DORAs arising, the market for these medications is likely to grow.

Challenges in the dual orexin receptor antagonist market are:

1. Regulatory Hurdles: The regulatory process for the approval of DORA drugs is time-consuming and complex, especially in countries with strict pharmaceutical regulations. Companies need to overcome these issues to market their drugs on time.

2. Emerging Markets' Price Sensitivity: With demand for DORAs growing, price sensitivity is an area of difficulty, particularly in the emerging markets. Firms need to juggle the accessibility of their product alongside ensuring the same high level of quality and efficacy.

3. Alternative Treatment Competition: The DORA market competes with alternative treatments for sleep disorders, including benzodiazepines, melatonin, and other sedatives. Companies need to differentiate DORA-based therapies from these alternatives to remain competitive.

The challenges and drivers affecting the dual orexin receptor antagonist market mirror the dynamic nature of the sector. Although increased awareness, formulation advancements, and rising healthcare investment are fueling growth, regulatory barriers and price sensitivity remain current challenges. By addressing these variables, companies can more effectively deal with the intricacies of the market and take advantage of emerging opportunities.

List of Dual Orexin Receptor Antagonist Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dual orexin receptor antagonist companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dual orexin receptor antagonist companies profiled in this report include-

• Merck
• Eisal
• Idorsia
• Takeda

Dual Orexin Receptor Antagonist Market by Segment

The study includes a forecast for the global dual orexin receptor antagonist market by type, application, and region.

Dual Orexin Receptor Antagonist Market by Type [Value from 2019 to 2031]:

• Suvorexant
• Lemborexant
• Daridorexant

Dual Orexin Receptor Antagonist Market by Application [Value from 2019 to 2031]:

• Hospital & Clinic
• Retail Pharmacies
• Others

Dual Orexin Receptor Antagonist Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Dual Orexin Receptor Antagonist Market

The market for dual orexin receptor antagonist (DORA) has been expanding very quickly as a result of increasing interest in sleep disorders like insomnia and other neurological conditions associated with it. This category of drugs, acting on the orexin receptors involved in wakefulness regulation, is gaining popularity across the world because of its efficiency in inducing sleep without side effects compared to conventional sedatives. Major developments in the DORA market have been noted in key pharma markets such as the United States, China, Germany, India, and Japan, where research, clinical trials, and product approvals remain to define the market scenario.

• United States: In the United States, the market for dual orexin receptor antagonist has experienced considerable growth, especially with the regulatory approval of products such as Suvorexant (Balsara), the first DORA to be approved by the FDA for the treatment of insomnia. An increased need for effective treatments, fueled by the rising incidence of sleep disorders, has driven further interest in DORAs. U.S. market is marked by swift uptake of novel sleep aids, with continuous research aimed at enhancing the safety and effectiveness of the drugs. The regulatory environment is favorable, offering a clear line for further DORA drugs to come into the market.
• China: China is experiencing swift growth in the market for DORA as awareness about sleep disorders rises and more attention is being focused on mental health. The Chinese government has been investing in healthcare infrastructure, and increasing numbers of people are looking for treatments for insomnia and associated conditions. Although DORAs are relatively new to the market, consumers are increasingly interested in innovative sleep aids. Clinical trials and research are ongoing, and the market is likely to grow as the demand for safe and effective treatment for sleep disorders grows nationwide.
• Germany: Germany's DORA market is expanding steadily, with growing awareness of sleep disorders such as insomnia and narcolepsy. With the healthcare system providing significant support for mental health conditions, Germany has emerged as a leading market for the uptake of new treatments. Regulatory approvals for DORAs like Suvorexant and other upcoming drugs have improved treatment options for patients. Germany is targeting the betterment of sleeping quality and encouragement of safer alternatives to conventional sedatives. Having robust pharmaceutical corporations in Germany enhances ongoing research and development in this sector.
• India: In India, the DORA market remains nascent with very limited presence of orexin receptor-targeted drugs for sleeping disorders. Nonetheless, with the rising prevalence of insomnia and increased awareness of mental illness, there is a growing demand for successful treatments. The market is dominated by the embracement of Western medicine, yet there is a desire for cheaper drugs. Regulatory authorities in India are considering the approval of DORAs, and the market is expected to expand as knowledge of the advantages of DORA-based therapies spreads among the healthcare community and consumers.
• Japan: Japan has experienced strong growth in the DORA market, especially with the rising incidence of sleep disorders due to lifestyle and aging populations. Japanese pharmaceutical firms are at the forefront of creating DORA-based treatments, including the approval of Suvorexant. The need for safe and non-habit-forming sleep aids is increasing, and DORAs are a very promising treatment option. Japan's strong healthcare system and regulatory environment facilitate the ongoing development of this market. The emphasis is on providing effective treatments that ensure healthy sleep without the threat of dependence.

Features of the Global Dual Orexin Receptor Antagonist Market

Market Size Estimates: Dual orexin receptor antagonist market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Dual orexin receptor antagonist market size by type, application, and region in terms of value ($B).

Regional Analysis: Dual orexin receptor antagonist market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the dual orexin receptor antagonist market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dual orexin receptor antagonist market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the dual orexin receptor antagonist market by type (suvorexant, lemborexant, and daridorexant), application (hospital & clinic, retail pharmacies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dual Orexin Receptor Antagonist Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Dual Orexin Receptor Antagonist Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Dual Orexin Receptor Antagonist Market by Type
  • 3.3.1: Suvorexant
  • 3.3.2: Lemborexant
  • 3.3.3: Daridorexant
• 3.4: Global Dual Orexin Receptor Antagonist Market by Application
  • 3.4.1: Hospital & Clinic
  • 3.4.2: Retail Pharmacies
  • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Dual Orexin Receptor Antagonist Market by Region
• 4.2: North American Dual Orexin Receptor Antagonist Market
  • 4.2.1: North American Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.2.2: North American Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.3: European Dual Orexin Receptor Antagonist Market
  • 4.3.1: European Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.3.2: European Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.4: APAC Dual Orexin Receptor Antagonist Market
  • 4.4.1: APAC Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.4.2: APAC Market by Application: Hospital & Clinic, Retail Pharmacies, and Others
• 4.5: ROW Dual Orexin Receptor Antagonist Market
  • 4.5.1: ROW Market by Type: Suvorexant, Lemborexant, and Daridorexant
  • 4.5.2: ROW Market by Application: Hospital & Clinic, Retail Pharmacies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Type
  • 6.1.2: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Application
  • 6.1.3: Growth Opportunities for the Global Dual Orexin Receptor Antagonist Market by Region
• 6.2: Emerging Trends in the Global Dual Orexin Receptor Antagonist Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Dual Orexin Receptor Antagonist Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dual Orexin Receptor Antagonist Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Merck
• 7.2: Eisal
• 7.3: Idorsia
• 7.4: Takeda